The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Karyopharm Therapeutics (Inst)
Travel, Accommodations, Expenses - Karyopharm Therapeutics
A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM).
 
Ulrik Niels Lassen
No Relationships to Disclose
 
Morten Mau-Soerensen
No Relationships to Disclose
 
Andrew L. Kung
Consulting or Advisory Role - ABT Molecular Imaging
Patents, Royalties, Other Intellectual Property - Molecular Imaging
 
Patrick Y. Wen
No Relationships to Disclose
 
Eudocia Quant Lee
No Relationships to Disclose
 
Scott R. Plotkin
No Relationships to Disclose
 
Aida Muhic
No Relationships to Disclose
 
Tami Rashal
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Tony Williams
Employment - Karyopharm Therapeutics
 
Dilara McCauley
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Joel Ellis
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Jean-Richard Saint-Martin
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Robert Carlson
Employment - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Ran Frenkel
Employment - Karyopharm Therapeutics
Leadership - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Sharon Shacham
Employment - Karyopharm Therapeutics
Leadership - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Mansoor Raza Mirza
Leadership - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
Consulting or Advisory Role - Karyopharm Therapeutics
 
Michael Kauffman
Employment - Karyopharm Therapeutics
Leadership - Karyopharm Therapeutics
Stock and Other Ownership Interests - Karyopharm Therapeutics
 
Andrew B. Lassman
Consulting or Advisory Role - Agenus; Amgen; Celgene; Foundation Medicine; Genentech/Roche; HERON; Midatech Pharma; Novartis; RadMD; Sigma-Tau; Stemline Therapeutics
Research Funding - Abbvie (Inst); Aeterna Zentaris (Inst); Agenus (Inst); Amgen (Inst); Bayer/Onyx (Inst); Boehringer Ingelheim (Inst); Celldex (Inst); E-therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Plexxikon (Inst); Stemline Therapeutics (Inst)
Travel, Accommodations, Expenses - Novartis; Novocure